Rossari BiotechNSE:ROSSARI +1.03%87 Net Current Asset Value is ₹50.64 as of Mar. 2026, which is 100% below its 10-year median of 11.97. GuruFocus rates NSE:ROSSARI with a GF Score™ of 87/100 and a GF Value™ of ₹1,004.33 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 945 Chemicals companies, Rossari Biotech ranks worse than 70.16% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Rossari Biotech's net current asset value per share for the quarter that ended in Mar. 2026 was ₹50.64.
The historical rank and industry rank for Rossari Biotech's Net Current Asset Value or its related term are showing as below:
NSE:ROSSARI'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.47 Med: 11.97 Max: 31.89
Current: 10.38
During the past 9 years, the highest Price-to-Net-Current-Asset-Value Ratio of Rossari Biotech was 31.89. The lowest was 7.47. And the median was 11.97.
NSE:ROSSARI's Price-to-Net-Current-Asset-Value is ranked worse than 70.16% of 945
companies
in the Chemicals industry
Industry Median: 5.17
vs NSE:ROSSARI: 10.38
Rossari Biotech (NSE:ROSSARI) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Rossari Biotech Net Current Asset Value Related Terms
Rossari Biotech Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Rossari Biotech's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ROSSARI vs LIN, SHW, ECL: Net Current Asset Value Comparison
For the Specialty Chemicals subindustry, Rossari Biotech's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossari Biotech Price-to-Net-Current-Asset-Value vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Rossari Biotech's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Rossari Biotech's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹50.64 mean?
Rossari Biotech (NSE:ROSSARI) has a Net Current Asset Value of ₹50.64 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Rossari Biotech and its competitors. This is 323% above median its historical median of 11.97. Over the past decade, Rossari Biotech's Net Current Asset Value has ranged from 7.47 to 31.89. According to the industry distribution chart, Rossari Biotech ranks #663 out of 945 companies in the Chemicals industry, placing it in the top 70.2%.
Is Rossari Biotech's Net Current Asset Value too high?
Rossari Biotech's current Net Current Asset Value of ₹50.64 is 323% above median its 10-year median of 11.97. Over the past 10 years, this metric has ranged from a low of 7.47 to a high of 31.89. Based on the distribution chart, Rossari Biotech ranks #663 out of 945 companies in the Chemicals industry, which is below the industry midpoint. Overall, Rossari Biotech has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's Net Current Asset Value compare to LIN and SHW?
According to the Chemicals industry distribution chart, Rossari Biotech ranks #663 out of 945 companies for Net Current Asset Value. This places Rossari Biotech in the lower half of its industry. The industry median Net Current Asset Value is 5.17. Historically, Rossari Biotech's own Net Current Asset Value has ranged from 7.47 to 31.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Chemicals company?
The median Net Current Asset Value among Chemicals companies is 5.17, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Rossari Biotech and its competitors. For the Chemicals industry, the median Net Current Asset Value is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossari Biotech's current Net Current Asset Value is ₹50.64, which is 323% above median its own 10-year median of 11.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1,004.33, compared to a current price of ₹524.20 — trading 47.8% below its estimated fair value. The current Net Current Asset Value is ₹50.64, which is 323% above median its 10-year median of 11.97. Rossari Biotech's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current Net Current Asset Value is ₹50.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹524.20 is trading 47.8% below its estimated GF Value™ of ₹1,004.33.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
Net Current Asset Value: ₹50.64 (323% above median its 10-year median of 11.97)
GF Value™: ₹1,004.33 vs. price of ₹524.20 (47.8% below fair value)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
87GF Score
Get the complete analysis for NSE:ROSSARI
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
